Nanoform, an innovative drug enabling nanotechnology company, has received a Seal of Excellence from the European Commission for its “Nanomedicines of Tomorrow” project. The award certifies that the
proposal is of a high quality with an exceptional degree of innovation and impact.
The “Nanomedicines of Tomorrow” project applies proprietary nanonization technology to reduce rates of clinical attrition through improved drug solubility and bioavailability. Nanoform’s nanoparticle engineering technology will significantly increase the number of drugs reaching the market, with patients around the world benefiting from the development of more efficient treatments.
The Seal of Excellence is an initiative that began in 2015 to provide validation for proposals that have reached the stringent threshold for Horizon 2020. The project was evaluated by an international panel
of independent experts to ensure that the rigorous assessment criteria of excellence, impact, quality and efficiency of implementation were met.